Interferon gamma production in blood lymphocytes correlates with disability score in multiple sclerosis patients

Multiple Sclerosis

Volumn 6, Issue 1, 2000, Pages 19-23

  Petereit, H F ^a   Richter, N ^b   Pukrop, R ^b   Bamborschke, S ^b  

^a Klinik und Poliklinik fur Neurologie   (Germany)

^b NONE

Author keywords

Axonal damage; Disability; Inflammation; Interferon gamma; Multiple sclerosis

Indexed keywords

GAMMA INTERFERON;

ADULT; ARTICLE; CLINICAL ARTICLE; DISABILITY; DISEASE DURATION; DISEASE EXACERBATION; FEMALE; HUMAN; INFLAMMATION; INTERFERON PRODUCTION; LYMPHOCYTE; MALE; MULTIPLE SCLEROSIS;

EID: 0034023285     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/135245800678827383     Document Type: Article

References (31)

1. Olsson T. (1994) Multiple sclerosis: cerebrospinal fluid. Ann Neurol 36 (Suppl) 100-102.
2. Cannella B, Raine CS. (1995) The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol 37: 424-435.
3. Navikas V, Link H. (1997) Review: cytokines and the pathogenesis of multiple sclerosis. J Neurosci Res 45: 322-333.
4. Panitch HS, Hirsch RL, Haley AS, Johnson KP. (1987) Exacerbation of multiple sclerosis in patients treated with gamma interferon. Lancet 1: 893-895.
5. Noronha A, Toscas A, Jensen MA. (1993) Interferon beta decreases T cell activation and interferon gamma production in multiple sclerosis. J Neuroimmunol 46: 145-154.
6. Dayal AS, Jensen MA, Lledo A, Arnason BGW. (1995) Interferon-gamma-secreting cells in multiple sclerosis patients treated with interferon beta-1b. Neurology 45: 2173-2177.
7. Phillippe J et al. (1996) In vitro TNF-alpha, IL-2 and IFN-gamma production as markers of relapses in multiple sclerosis. Clin Neurol Neurosurg 98: 286-290.
8. Dettke M, Scheidt P, Prange H, Kirchner H. (1997) Correlation between interferon production and clinical disease activity in patients with multiple sclerosis. J Clin Immunol 17: 293-300.
9. Crucian B et al. (1995) Alterations in peripheral blood mononuclear cell cytokine production in response to phytohemagglutinin in multiple sclerosis patients. Clin Diagn Lab Immunol 2: 766-769.
10. Revel M et al. (1995) Antagonism of interferon beta on interferon gamma: inhibition of signal transduction in vitro and reduction of serum levels in multiple sclerosis patients. Multiple Sclerosis 1 (Suppl 1): 5-11.
11. Petereit HF, Bamborschke S, Esse AD, Heiss WD. (1997) Interferon gamma producing blood lymphocytes are decreased by interferon beta therapy in patients with multiple sclerosis. Multiple Sclerosis 3: 180-183.
12. Link H. (1998) The cytokine storm in multiple sclerosis. Multiple Sclerosis 4: 12-15.
13. Sharif MK, Hentges R. (1991) Association between tumor necrosis factor alpha and disease progression in patients with multiple sclerosis. New Engl J Med 325:467-542.
14. McDonnell GV, Hawkins SA. (1996) Primary progressive multiple sclerosis: a distinct syndrome? Multiple Sclerosis 2: 137-141.
15. Kurtzke JF et al. (1977) Studies on the natural history of multiple sclerosis. J Chron Dis 30: 819-830.
16. Thompson AJ et al. (1986) A clinical and laboratory study of benign multiple sclerosis. Quart J Med 58: 69-80.
17. Kurtzke JF. (1983) Rating neurological impairment in multiple sclerosis: an expanded disability rating scale (EDSS). Neurology 13: 1444-1452.
18. Kesselring J. (1997) Epidemiologie. In: Kesselring J (ed.) Multiple Sklerose, 3rd edn. Kohlhammer Verlag: Stuttgart pp 75-76.
19. Jackson HJ, McGorry PD, Dudgeon P (1995) Prodromal symptoms of schizophrenia in first-episode patients: prevalence and specificity. Comprehensive Psych 36: 241-250.
20. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. (1995) Interferon beta-lb in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 45: 1277-1285.
21. Gawne-Cain ML et al. (1998) MRI lesion volume measurement in multiple sclerosis and its correlation with disability: a comparison of fast fluid attenuated inversion recovery and spin echo sequences. J Neurol Neurosurg Psych 64: 197-203.
22. O'Riordan JI et al. (1998) The prognostic value of brain MRI in clinically isolated syndroms of the CNS. A 10-year follow-up. Brain 121: 495-503.
23. Evans AC, Frank JA, Antel J, Miller DH. (1997) The role of MRI in clinical trials of Multiple sclerosis: comparison of image processing techniques. Ann Neurol 41: 125-132.
24. Campell IL, Iscaro A, Harrison LC. (1988) IFN-gamma and tumor necrosis factor alpha. Cytotoxicity to murine islets of Langerhans. J Immunol 141: 2325-2329.
25. Adamson GM, Billings RE. (1993) Cytokine toxicity and induction of NO synthase activity in cultured mouse hepatocytes. Toxicol Appl Pharmacol 119: 100-107.
26. Arnason BG et al. (1997) Role of interferons in demyelinating diseases. J Neural Transmission (Suppl 49): 117-123.
27. Vartanian T, Li Y, Zhao M, Stefansson K. (1995) Interferon gamma induced oligodendrocyte cell death: implications for the pathogenesis of multiple sclerosis. Molecular Med 1: 732-743.
28. Moreau T et al. (1996) Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain 119: 225-237.
29. Trapp BD et al. (1998) Axonal transection in the lesions of multiple sclerosis. N Engl J Med 338: 278-285.
30. Fergueson B, Matyszak MK, Esiri MM, Perry VH. (1997) Axonal damage in acute multiple sclerosis lesions. Brain 120: 393-399.
31. Chao CC et al. (1992) Activated microglia mediate neuronal cell injury via a nitric oxide mechanism. J Immunol 149: 2736-2741.